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Background: In stable pts, T-wave alternans (TWA) predicts mortality, although the relationship in pts with NSTEACS is not well described. 
Ranolazine, a late INa inhibitor, modulates repolarization and has antiarrhythmic properties.
methods: Maximum TWA was calculated by Modified Moving Average method in cases and age/sex-matched controls with EF <40% and VT ≥8 
beats or SCD from MERLIN-TIMI 36 trial. All pts received standard therapy for NSTEACS plus ranolazine (N=109) or placebo (N=101) and had 
continuous ECG (cECG) recording for up to 7 days at admission. cECGs from 210 pts on Day 1 and 156 of these pts on Day 6 were interpretable for 
analysis after excluding pts with AF or ectopy.
results: Median max TWA on Day 1 was 35 μV (IQR 28,43). TWA ≥47 μV (established cutpoint) on Day 1 correlated with 1-year mortality, CV death, 
and VT ≥4 beats (Table). On Day 6, median TWA was 36 μV (IQR 27,46). TWA ≥43 on Day 6 was associated with 1-year CV death (OR 4.50, 95%CI 
1.4-14.3, p=0.011) in pts treated with placebo but not in pts treated with ranolazine (HR 0.30, 95% CI 0.04-2.6, p=0.27; p interaction 0.039). 
Overall, ranolazine did not reduce TWA between Days 1 and 6, although exploratory analyses suggest a reduction in TWA in pts with elevated baseline 
TWA ≥47μV.
conclusions: (1) In pts with NSTEACS, TWA ≥47 μV on Day 1 is associated with increased risk of total and CV mortality and NSVT at 1 year; (2) In 
pts with persistently elevated TWA, treatment with ranolazine may modify risk of mortality over 1 year, although further validation is needed.
Odds Ratios of T-wave alternans for different endpoints
Day 1 Odds Ratio Lower limit of 95% CI Upper limit of 95% CI p value
Overall mortality 3.0 1.3 7.0 0.010
CV death 2.8 1.2 6.6 0.020
VT ≥4 beats 2.4 1.1 5.0 0.024
CVD + VT ≥4 beats 2.3 1.1 5.0 0.034
